SCHEMBL6632149

SCHEMBL6632149

CC(C)n1cc(C(=O)NCc2ccc(Cl)cc2)c(=S)c2cc(CCCO)sc21

nearest known ligand 0.82

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6706463 0.90 KCNH2 (0.54) KCNH2
SCHEMBL6340773 0.90
SCHEMBL6632019 0.88 KCNH2 (0.56) KCNH2
SCHEMBL6632676 0.86 KCNH2 (0.44) KCNH2
SCHEMBL6636156 0.85 KCNH2 (0.45) KCNH2
SCHEMBL6635373 0.84 KCNH2 (0.41) KCNH2
SCHEMBL6632748 0.84 KCNH2 (0.44) KCNH2
SCHEMBL6667041 0.83 KCNH2 (0.66) KCNH2
SCHEMBL6634109 0.81
SCHEMBL6632771 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421089-A1 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS Pharmacia & Upjohn Company (US) 2004-05-26 EP claimed
US-6620810-B2 Treating a herpesvirus infection, atherosclerosis or restenosis PHARMACIA & UPJOHN COMPANY 2003-09-16 US claimed
US-20030109542-A1 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2003-06-12 US claimed
WO-2003020729-A1 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANT IVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-03-13 WO claimed
EP-1421089-A1 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS Pharmacia & Upjohn Company (US) 2004-05-26 EP disclosed
US-6620810-B2 Treating a herpesvirus infection, atherosclerosis or restenosis PHARMACIA & UPJOHN COMPANY 2003-09-16 US disclosed
US-20030109542-A1 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2003-06-12 US disclosed
WO-2003020729-A1 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANT IVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109542-A1 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents IRF3, IRAK4, IFNAR1 KCNH2 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.